Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 3/2020

01-03-2020 | Original Research Paper

Tachykinin-1 receptor antagonism suppresses substance-P- and compound 48/80-induced mast cell activation from rat mast cells expressing functional mas-related GPCR B3

Authors: Muhammad N. A. Sahid, Shuang Liu, Masaki Mogi, Kazutaka Maeyama

Published in: Inflammation Research | Issue 3/2020

Login to get access

Abstract

Objective

Mice and rats are important animal models for mast cell (MC) study. However, rat Mas-related-GPCR-B3 receptor (MRGPRB3) has been less studied than its mouse counterpart. Therefore, we aimed to characterize rat MRGPRB3.

Methods

Mrgprb3 mRNA expression was assessed in peritoneal cells (RPCs) and peritoneal MCs (RPMCs) of wild-type rats, RPCs of MC-deficient rats, and RBL-2H3 cells by reverse-transcriptase polymerase chain reaction (RT-PCR). RPMCs, MRGPRX2-transfected and non-transfected RBL-2H3 cells were activated by 15–30 min incubation with DNP-BSA, substance-P (SP), or compound-48/80. L732138 or CP96344 was used as a tachykinin/neurokinin-1-receptor antagonist. Histamine release from MCs was measured by HPLC fluorometry.

Results

Mrgprb3 mRNA expression was found in all cells, with the highest level in wild-type RPCs. All cells responded to DNP-BSA, but only MRGPRX2-transfected-RBL-2H3 cells and RPMCs responded to all activators. L732138 (0.1–10 μM) and CP96344 (1–100 μM) suppressed SP (10 μM)-induced RPMC activation. L732138 inhibition was dose independent, whereas CP96344 inhibition occurred in a dose-dependent manner. Additionally, only CP96344 suppressed SP (100 μM)- and compound-48/80 (10 μg/mL)-induced RPMC activation.

Conclusions

RPMCs expressing functional MRGPRB3 response upon MRGPRX2 ligands to regulated MC-mediated activities. It`s provide novel insights for future pseudo-allergic studies in rodents.
Appendix
Available only for authorised users
Literature
1.
Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, Furuno M, Ogasawara H, Edamura K, Takagi H, Iwamura H, Noguchi M, Naito T. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res Commun. 2006;349:1322–8.CrossRef
2.
Mousli M, Bueb JL, Bronner C, Rouot B, Landry Y. G Protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci. 1990;11(9):358–62.CrossRef
3.
Chahdi A, Fraundorfer PF, Beaven MA. Compound 48/80 activates mast cell phospholipase D via heterotrimeric GTP-binding proteins. J Pharmacol Exp Ther. 2000;292(1):122–30.PubMed
4.
Palomaki VA, Laitinen JT. The basic secretagogue compound 48/80 activates G proteins indirectly via stimulation of phospholipase d-lysophosphatidic acid receptor axis and 5-HT1A receptors in rat brain sections. Br J Pharmacol. 2006;147(6):596–606.CrossRef
5.
Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Disc. 2008;7(1):41–53.CrossRef
6.
Ohsawa Y, Hirasawa N. The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. Allergol Int. 2014;63:533–42.CrossRef
7.
Azimi E, Reddy VB, Shade K-TC, Anthony RM, Talbot S, Pereira PJS, Lerner EA. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. JCI Insight. 2016;1(16):e89362.
8.
Dong X, Han S-K, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell. 2001;106:619–32.CrossRef
9.
Liu Q, Tang Z, Surdenikova L, Kim S, Patel KN, Kim A, Ru F, Guan Y, Weng H-J, Geng Y, Undem BJ, Kollarik M, Chen Z-F, Anderson DJ, Dong X. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell. 2009;139:1353–65.CrossRef
10.
Robas N, Mead E, Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J Biol Chem. 2003;278(45):44400–4.CrossRef
11.
Kamohara M, Matsuo A, Takasaki J, Kohda M, Matsumoto M, Matsumoto S, Soga T, Hiyama H, Kobori M, Katou M. Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides. Biochem Biophys Res Commun. 2005;330:1146–52.CrossRef
12.
Nothacker H-P, Wang Z, Zeng H, Mahata SK, O’Connor DT, Civelli O. Proadrenomedullin N-terminal peptide and cortistatin activation of MrgX2 receptor is based on a common structural motif. Eur J Pharmacol. 2005;519:191–3.CrossRef
13.
McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, Dong X. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519(7542):237–41.CrossRef
14.
Zhang T, Che D, Liu R, Han S, Wang N, Zhang Y, Pundir P, Cao J, Lv Y, Yang L, Wang J, Ding M, Dong X, He L. Typical antimicrobials induced mast cell degranulation and anaphylactoid reactions via MrgprX2 and its murine homologue Mrgprb2. Eur J Immunol. 2017;47(11):1949–58.CrossRef
15.
Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci. 2004;74:1445–633.CrossRef
16.
Fridmanis D, Roga A, Klovins J. ACTH receptor (MC2R) specificity: what do we know about underlying molecular mechanisms? Front Endocrinol. 2017;8:13.CrossRef
17.
Tusnady GE, Simon I. Principles governing amino acid composition of integral membrane proteins: application to topology prediction. J Mol Biol. 1998;283:489–506.CrossRef
18.
Tusnady GE, Simon I. The HMMTOP transmembrane topology prediction server. Bioinformatics. 2001;17:849–50.CrossRef
19.
Omasits U, Ahrens CH, Muller S, Wollscheid B. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics. 2014;30(6):884–6.CrossRef
20.
Skrabanek L, Campagne F, Weinstein H. Building protein diagrams on the web with the residue-based diagram editor RbDe. Nucleic Acids Res. 2003;31:3856–8.CrossRef
21.
Kiyoi T, Liu S, Sahid MNA, Shudou M, Ogasawara M, Mogi M, Maeyama K. Morphological and functional analysis of beige (Chediak–Higashi syndrome) mouse mat cells with giant granules. Int Immunopharmacol. 2019;69:202–12.CrossRef
22.
Yamatodani A, Fukuda H, Iwaeda T, Watanabe T, Wada H. HPLC determination of plasma and brain histamine without previous purification of biological samples: cation exchange chromatography coupled with post-column derivatization fluorometry. J Chromatogr. 1985;344:115–23.CrossRef
23.
Aun MV, Bonamichi-Santos R, Arantes-Costa FM, Kalil J, Giavina-Bianchi P. Animal models of asthma: utility and limitations. J Asthma Allergy. 2017;10:293–301.CrossRef
24.
Reber LL, Marichal T, Galli SJ. New models for analyzing mast cell function in vivo. Trends Immunol. 2012;33(12):613–25.CrossRef
25.
Lei Y, Gregory JA, Nilsson GP, Adner M. Insights into mast cell functions in asthma using mouse models. Pulm Pharmacol Ther. 2013;26(5):532–9.CrossRef
26.
Kucharewicz I, Bodzenta-Lukaszyk A, Buczko W. Experimental asthma in rats. Pharmacol Rep. 2008;60(6):783–8.PubMed
27.
Oka T, Kalesnikoff J, Starkl P, Tsai M, Galli SJ. Evidence questioning cromolyn’s effectiveness and selectivity as a “mast cell stabilizer” in mice. Lab Invest. 2012;92(10):1472–82.CrossRef
28.
Arizono N, Kasugai T, Yamada M, Okada M, Morimoto M, Tei H, Newlands GF, Miller HR, Kitamura Y. Infection of Nippostrongylus brasiliensis induces development of mucosal-type but not connective tissue-type mast cells in genetically mast cell-deficient Ws/Ws rats. Blood. 1993;81(10):2572–8.CrossRef
29.
Barsumian EL, Isersky C, Petrino MG, Siraganian RP. IgE-induced histamine release from rat basophilic leukemia cell lines: isolation of releasing and non-releasing clones. Eur J Immunol. 1981;11:317–23.CrossRef
30.
Passante E, Frankish N. The RBL-2H3 cell line: its provenance and suitability as a model for the mast cell. Inflamm Res. 2009;58:737–45.CrossRef
31.
Lai J-P, Lai S, Tuluc F, Tansky MF, Kilpatrick LE, Leeman SE, Douglas SD. Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci USA. 2008;105(34):12605–10.CrossRef
32.
Snider RM, Longo KP, Drozda SE, Lowe JA III, Leeman SE. Effect of CP-96345, a nonpeptide substance P receptor antagonist, on salivation in rats. Proc Natl Acad Sci USA. 1991;88:10042–4.CrossRef
33.
Griesbacher T, Donnerer J, Legat FJ, Lembeck F. CP-96345, a non-peptide antagonist of substance P: II. Actions on substance P-induced hypotension and bronchoconstriction, and on depressor reflexes in mammals. Naunyn-Schmiedeberg’s Arch Pharmacol. 1992;346:323–7.
34.
Yashpal K, Radhakrishnan V, Coderres TJ, Henry JL. CP-96345, but not its stereoisomer, CP-96344, blocks the nociceptive responses to intrathecally administered substance P and to noxious thermal and chemical stimuli in the rat. Neuroscience. 1993;52(4):1039–47.CrossRef
35.
Jacob S, Deyo DJ, Cox RA, Jacob RK, Herndon DN, Traber DL, Hawkins HK. Substance P antagonist CP-96345 blocks lung vascular leakage and inflammation more effectively than its stereoisomer CP-96344 in a mouse model of smoke inhalation and burn injury. Toxical Mech Meth. 2010;20(4):197–203.CrossRef
36.
Leffler A, Ahlstedt I, Engberg S, Svensson A, Billger M, Oberg L, Bjursell MK, Lindstrom E, von Mentzer B. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol. 2009;77(9):1522–30.CrossRef
37.
Calcieri MA, Macleod AM, Underwood D, Shiao LL, Ber E, Sadowski S, Yu H, Merchant KJ, Swain CJ, Strader CD, Fong TM. Characterization of the interaction of N-acyl-l-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J Biol Chem. 1994;269(9):6587–91.
Metadata
Title
Tachykinin-1 receptor antagonism suppresses substance-P- and compound 48/80-induced mast cell activation from rat mast cells expressing functional mas-related GPCR B3
Authors
Muhammad N. A. Sahid
Shuang Liu
Masaki Mogi
Kazutaka Maeyama
Publication date
01-03-2020
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 3/2020
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-020-01319-z

Other articles of this Issue 3/2020

Inflammation Research 3/2020 Go to the issue

Original Research Paper

miR-425-5p improves inflammation and septic liver damage through negatively regulating the RIP1-mediated necroptosis

Original Research Paper

Crocin alleviates lipopolysaccharide-induced acute respiratory distress syndrome by protecting against glycocalyx damage and suppressing inflammatory signaling pathways

Original Research Paper

Identification and evaluation of hub mRNAs and long non-coding RNAs in neutrophils during sepsis

Original Research Paper

Thirty days after anterior cruciate ligament transection is sufficient to induce signs of knee osteoarthritis in rats: pain, functional impairment, and synovial inflammation

Review

Tissue-resident memory T cells in the skin

Original Research Paper

lncRNA H19 sponging miR-93 to regulate inflammation in retinal epithelial cells under hyperglycemia via XBP1s
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits